keyword
MENU ▼
Read by QxMD icon Read
search

immunohematology

keyword
https://www.readbyqxmd.com/read/29398823/importance-of-indigenous-lectin-panel-in-immunohematology
#1
Ritam Chakrabarty, Suvro Sankha Datta, Sudipta Sekhar Das, Susanta Ghosh
No abstract text is available yet for this article.
January 2018: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/29378149/clinical-and-laboratory-profile-of-anti-m
#2
Debapriya Basu, Sabita Basu, Mahua Reddy, Kaushik Gupta, Mammen Chandy
Anti-M is a frequently detected naturally occurring antibody that has been reported in various clinical settings and also in voluntary donors. We describe here the clinical and laboratory findings of 11 cases with anti-M detected at our center. This report is a retrospective study in which we reviewed our immunohematology laboratory records for cases involving anti-M. Both donor and patient data from a 28-month period (September 2014 to December 2016) were reviewed. During this period, 11 examples of anti-M were detected (8 patients, 1 voluntary whole blood donor, and 1 hematopoietic stem cell donor...
December 2017: Immunohematology
https://www.readbyqxmd.com/read/29378148/hemovigilance-and-the-notify-library
#3
Barbee I Whitaker, D M Strong, Manish J Gandhi, Evangelia Petrisli
Hemovigilance systems allow reporting of adverse occurrences associated with blood transfusion to a central database where events can be reviewed and analyzed for the benefit of patients and donors. Hemolytic and serologic transfusion reactions are among the many types of reactions reported to these systems. The Notify Library, a database of adverse events associated with medical products of human origin, has incorporated hemovigilance into its didactic resources. Students and practitioners are encouraged to use the electronic library and to further enhance this resource through review and recommendation of additional publications in the area of immunohematology...
December 2017: Immunohematology
https://www.readbyqxmd.com/read/29344016/coding-of-tissue-and-cell-preparations-using-eurocode
#4
REVIEW
Ralf Knels, Kirstin Stüpmann, Axel Pruß, Jan Klerke, Joachim Kardoeus, Jens Hiller
Traceability of products requires their unique identification. In Germany blood products have been encoded by Eurocode since 1998. EU Directives 2004/23/EC, 2006/86/EC and 2015/565/EC demanded unique identification and safe traceability procedure also for tissues and cells. Eurocode IBLS e.V. and the German Society of Transfusion Medicine and Immunohematology (DGTI) working parties '!' within the Single European Code (SEC). Several data elements of Eurocode can be used to create the complete SEC data structure, except the tissue establishment number...
November 2017: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/29070972/congress-of-the-german-society-of-transfusion-medicine-and-immunohematology-50th-anniversary
#5
EDITORIAL
Harald Klüter, Birgit Gathof, Peter Schlenke
No abstract text is available yet for this article.
September 2017: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/29051799/red-cell-genotyping-precision-medicine-a-conference-summary
#6
REVIEW
Gregory A Denomme, Waseem Q Anani, Neil D Avent, Gregor Bein, Lynne B Briggs, Razvan C Lapadat, Celina Montemayor, Maria Rios, Maryse St-Louis, Lynne Uhl, Silvano Wendel, Willy A Flegel
This review summarizes the salient points of the symposium 'Red Cell Genotyping 2015: Precision Medicine' held on 10 September 2015 in the Masur Auditorium of the National Institutes of Health. The specific aims of this 6th annual symposium were to: (1) discuss how advances in molecular immunohematology are changing patient care; (2) exemplify patient care strategies by case reports (clinical vignettes); (3) review the basic molecular studies and their current implications in clinical practice; (4) identify red cell genotyping strategies to prevent alloimmunization; and (5) compare and contrast future options of red cell genotyping in precision transfusion medicine...
October 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/29043828/a-lu-16-individual-with-antibodies
#7
Carole Éthier, Cynthia Parent, Anne-Sophie Lemay, Nadia Baillargeon, Geneviève Laflamme, Josée Lavoie, Josée Perreault, Maryse St-Louis
Antibodies against Lutheran blood group antigens have been observed during first-time pregnancy. Samples from a woman of African descent were tested in our immunohematology laboratory on several occasions since 2001. Her samples were phenotyped as Lu(a+b-), and anti-Lub was suspected but not identified. She was asked to make autologous donations in preparation for her delivery, which she did. In 2010, two antibodies were identified: anti-Lea and -Lub. Six years later, a third investigation was requested. This time, an antibody directed at a high-prevalence Lutheran antigen was found in addition to the anti-Lea and -Lub previously observed...
September 2017: Immunohematology
https://www.readbyqxmd.com/read/29021165/preclinical-modeling-highlights-the-therapeutic-potential-of-hematopoietic-stem-cell-gene-editing-for-correction-of-scid-x1
#8
Giulia Schiroli, Samuele Ferrari, Anthony Conway, Aurelien Jacob, Valentina Capo, Luisa Albano, Tiziana Plati, Maria C Castiello, Francesca Sanvito, Andrew R Gennery, Chiara Bovolenta, Rahul Palchaudhuri, David T Scadden, Michael C Holmes, Anna Villa, Giovanni Sitia, Angelo Lombardo, Pietro Genovese, Luigi Naldini
Targeted genome editing in hematopoietic stem/progenitor cells (HSPCs) is an attractive strategy for treating immunohematological diseases. However, the limited efficiency of homology-directed editing in primitive HSPCs constrains the yield of corrected cells and might affect the feasibility and safety of clinical translation. These concerns need to be addressed in stringent preclinical models and overcome by developing more efficient editing methods. We generated a humanized X-linked severe combined immunodeficiency (SCID-X1) mouse model and evaluated the efficacy and safety of hematopoietic reconstitution from limited input of functional HSPCs, establishing thresholds for full correction upon different types of conditioning...
October 11, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28966502/rare-presentation-of-mixed-autoimmune-hemolytic-anemia-in-children-report-of-2-cases
#9
Preeti Rai, Geetika Sharma, Deeksha Singh, Jyoti Garg
Immune hemolytic anemia is characterized by clinical and laboratory features of hemolytic anemia with direct antiglobulin test (DAT) positivity. It could be autoimmune hemolytic anemia (AIHA), alloimmune, or drug-induced hemolysis based on the antigenic stimulus. Furthermore, based on thermal amplitude of autoantibody, AIHA is classified as warm (65%), cold (30%), and mixed (5%) type. Mixed AIHA is extremely rare in children and must be differentiated from warm AIHA with clinically insignificant cold agglutinins and cold hemagglutinin disease as their treatment is different...
October 2017: Journal of Laboratory Physicians
https://www.readbyqxmd.com/read/28905389/the-first-reported-case-of-concurrent-trimethoprim-sulfamethoxazole-induced-immune-hemolytic-anemia-and-thrombocytopenia
#10
Yevgeniy A Linnik, Edison W Tsui, Isabella W Martin, Zbigniew M Szczepiorkowski, Gregory A Denomme, Jerome L Gottschall, John M Hill, Nancy M Dunbar
BACKGROUND: Drug-induced immune hemolytic anemia (DIIHA) and drug-induced immune thrombocytopenia (DIIT) are rare but dangerous complications of pharmacotherapy that may be underrecognized in hematopoietic stem cell transplant (HSCT) patients due to overlap of signs and symptoms with those of more common disease processes. CASE REPORT: A 61-year-old woman with NK-cell deficiency and GATA-2-associated myelodysplastic syndrome, status post-recent allogeneic HSCT (Day +58), presented with 3 days of acute-onset severe back pain, muscle cramps, and increasingly dark urine...
December 2017: Transfusion
https://www.readbyqxmd.com/read/28854790/neopterin-and-soluble-cd14-levels-as-indicators-of-immune-activation-in-cases-with-low-anti-hcv-reactivity-and-true-hcv-infection
#11
MULTICENTER STUDY
Z Habip, P Sohrabi, S Saribas, R Caliskan, M Demirci, A Karakullukcu, K Atalik, P Yuksel, O Uysal, E Kosan, H Bahar Tokman, B Kocazeybek
Neopterin and soluble CD14 (sCD14) are detected at high levels in hepatitis C virus (HCV) infections. We aimed to evaluate the role of these plasma immune activation biomarkers, for the indirect assessment of immune activation status of patients with low anti-HCV reactivity and a HCV infection. Low anti-HCV reactivity group (LRG, n: 70), true positive HCV infection group (THG, 30) and healthy control group (HCG, 30) were analyzed in this study. We have used ELISA, HCV RIBA/LIA and HCV-RNA methods. Mean neopterin levels were significantly lower in LRG than THG (p <0...
2017: Acta Virologica
https://www.readbyqxmd.com/read/28729746/the-incidence-and-effects-of-alloimmunization-in-pregnancy-during-the-period-2000%C3%A2-%C3%A2-2013
#12
Marjana Jerković Raguž, Darinka Šumanovic Glamuzina, Jerko Brzica, Tonći Gruica
INTRODUCTION: The objective of the analysis was to examine the epidemiological aspects of maternal alloimmunization and to determine the most common antibody specificities resulting in hemolytic disease of the newborn (HDN). MATERIALS AND METHODS: The retrospective epidemiological study encompasses all pregnant women who underwent immunohematological screening and the newborn treated for HDN in the period from 2000 to 2013 in the Herzegovina region. RESULTS: The indirect Coombs test (ICT) detected antibodies against antigens in 384 (2...
July 2017: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/28657763/the-vel-blood-group-system-a-review
#13
Jill R Storry, Thierry Peyrard
The blood group antigen Vel has been one of immunohematology's greatest enigmas: the variation in antigen strength from one individual to another, the property of anti-Vel to readily hemolyze Vel+ red blood cells (RBCs), and the difficulty to screen for sufficient numbers of Vel- blood donors had made Vel a tough nut to crack. In 2013, a small, previously unknown protein called small integral membrane protein 1 (SMIM1) was identified on the RBC by three independent research groups using different approaches, and all three groups demonstrated that Vel- RBCs lacked SMIM1...
June 2017: Immunohematology
https://www.readbyqxmd.com/read/28576386/-identification-of-alloantibodies-and-their-associations-balance-sheet-of-3%C3%A2-years-at-the-regional-center-of-blood-transfusion-in-rabat-morocco-and-difficult-in-transfusion-management
#14
S Achargui, A Zidouh, S Abirou, F Z Merhfour, S Monsif, S Amahrouch, A El Ghobre, M El Halhali, H Temmara, A El Hryfy, M Motqi, A Satty, M Kandili, M Aghri, K Hajjout, M Benajiba
Red blood cell immunization can lead to delays or even an impasse in a transfusion. OBJECTIVES: Determine the specificities of the most common of alloantibodies and their associations to correct management of red blood cell transfused. METHODS AND MATERIALS: A retrospective study between 2013 and 2015 in immunohematology laboratories at the Blood Transfusion Center of Rabat in Morocco. The following data were studied: frequency, specificities of alloantibodies, blood group involved in alloimmunization and difficult of management of transfusion in case with association of alloantibodies...
November 2017: Transfusion Clinique et Biologique: Journal de la Société Française de Transfusion Sanguine
https://www.readbyqxmd.com/read/28474469/how-do-i-work-up-pretransfusion-samples-containing-anti-cd38
#15
Waseem Q Anani, Kathleen Duffer, Richard M Kaufman, Gregory A Denomme
Anti-CD38 is used to treat relapsed or treatment-refractory multiple myeloma. CD38 monoclonal antibodies, however, can interfere with routine blood bank serologic tests. Agglutination is observed at the indirect phase of testing as the drug binds to red blood cells (RBCs). Resolving the testing interference causes delays issuing RBC units to patients with anemia. A number of devised methods to eliminate or bypass the effects of anti-CD38 on serologic tests are in use but no panacea exists. The limitations of each method require each testing site tailor an approach to best fit their needs...
June 2017: Transfusion
https://www.readbyqxmd.com/read/28425753/applications-of-selected-cells-in-immunohematology-in-a-developing-country-case-studies
#16
Ravi C Dara, Aseem K Tiwari, Dinesh Arora, Subhasis Mitra, Geet Aggarwal, Devi P Acharya, Gunjan Bhardwaj
When an antibody is detected, its specificity should be determined and its likely clinical significance should be assessed. When one antibody has been identified, it becomes necessary to confirm the presence of additional significant antibodies to ensure that compatible blood is provided to the patient. To perform this confirmation, specific reagent red blood cells (RBCs) are selected; these are called selected cells. Though the most common use of selected cells is for antibody confirmation, they can also be used for several other immunohematologic applications...
January 2017: Immunohematology
https://www.readbyqxmd.com/read/28425751/development-of-red-blood-cell-autoantibodies-following-treatment-with-checkpoint-inhibitors-a-new-class-of-anti-neoplastic-immunotherapeutic-agents-associated-with-immune-dysregulation
#17
Laura L Cooling, John Sherbeck, Jonathon C Mowers, Sheri L Hugan
Ipilimumab, nivolumab, and pembrolizumab represent a new class of immunotherapeutic drugs for treating patients with advanced cancer. Known as checkpoint inhibitors, these drugs act to upregulate the cellular and humoral immune response to tumor antigens by inhibiting T-cell autoregulation. As a consequence, they can be associated with immune-related adverse events (irAEs) due to loss of self-tolerance, including rare cases of immune-related cytopenias. We performed a retrospective clinical chart review, including serologic, hematology, and chemistry laboratory results, of two patients who developed red blood cell (RBC) autoantibodies during treatment with a checkpoint inhibitor...
January 2017: Immunohematology
https://www.readbyqxmd.com/read/28425748/a-field-analysis-trial-comparing-the-turnaround-times-of-routine-and-stat-red-blood-cell-immunohematology-testing
#18
COMPARATIVE STUDY
Katie Sackett, Andrea Kjell, Abigail M Schneider, Claudia S Cohn
The turnaround time (TAT) for pre-transfusion testing is important for prompt clinical decision-making. TAT includes the time between the arrival of the sample and the initiation of testing, plus the processing time (PT) required to generate and report a result. The TAT in larger blood banks is mostly dependent upon the capability of the analyzer used. In smaller blood banks, where manual work is often performed, the TAT is dependent on availability and experience of staff, testing resources, and workload. Our site performed a comparative analysis of the ORTHO VISION® (Ortho Clinical Diagnostics, Raritan, NJ) and the Echo® (Immucor, Norcross, GA) blood bank analyzers, using the TAT and PT of standard blood bank tests as the outcome metrics...
January 2017: Immunohematology
https://www.readbyqxmd.com/read/28424562/immunological-and-hematological-reference-intervals-among-hiv-seronegative-pregnant-women-in-northwest-ethiopia
#19
Meaza Genetu, Debasu Damtie, Meseret Workineh, Biniam Mathewos Tebeje, Bamlaku Enawgaw, Tekalign Deressa
BACKGROUND: Pregnancy is a state characterized by profound physiological hematological changes. However, hematological reference intervals being used in clinical practice in Ethiopia are derived from nonlocal general populations, despite the significant variations reported previously. The aim of this study was to determine the immunological and hematological reference intervals in healthy pregnancy among HIV-seronegative pregnant women in northwest Ethiopia. MATERIALS AND METHODS: A total of 200 healthy, HIV-seronegative pregnant women were enrolled from February 2015 to June 2015 in a cross-sectional study setting at Gondar University Hospital...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28416603/high-throughput-immunogenetics-for-clinical-and-research-applications-in-immunohematology-potential-and-challenges
#20
Anton W Langerak, Monika Brüggemann, Frédéric Davi, Nikos Darzentas, Jacques J M van Dongen, David Gonzalez, Gianni Cazzaniga, Véronique Giudicelli, Marie-Paule Lefranc, Mathieu Giraud, Elizabeth A Macintyre, Michael Hummel, Christiane Pott, Patricia J T A Groenen, Kostas Stamatopoulos
Analysis and interpretation of Ig and TCR gene rearrangements in the conventional, low-throughput way have their limitations in terms of resolution, coverage, and biases. With the advent of high-throughput, next-generation sequencing (NGS) technologies, a deeper analysis of Ig and/or TCR (IG/TR) gene rearrangements is now within reach, which impacts on all main applications of IG/TR immunogenetic analysis. To bridge the generation gap from low- to high-throughput analysis, the EuroClonality-NGS Consortium has been formed, with the main objectives to develop, standardize, and validate the entire workflow of IG/TR NGS assays for 1) clonality assessment, 2) minimal residual disease detection, and 3) repertoire analysis...
May 15, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
keyword
keyword
33889
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"